These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 8033145)

  • 1. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer.
    Kobayashi H; Yagyu T; Inagaki K; Kondo T; Suzuki M; Kanayama N; Terao T
    Cancer; 2004 Feb; 100(4):869-77. PubMed ID: 14770446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
    McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
    Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
    Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of oral JM216 given twice daily.
    Beale P; Raynaud F; Hanwell J; Berry C; Moore S; Odell D; Judson I
    Cancer Chemother Pharmacol; 1998; 42(2):142-8. PubMed ID: 9654114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
    Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
    Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of treatment schedule on antitumor activity of glycolate-0,0'-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II).
    Suzumura Y; Kato T; Ueda R; Ota K
    Anticancer Res; 1989; 9(4):1083-8. PubMed ID: 2817790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.